Capeta Nova 500mg Tablet is a highly effective oral chemotherapy medication containing 500 mg of Capecitabine, a prodrug that selectively converts to 5-Fluorouracil (5-FU) within tumor cells. Manufactured by Nova, this oncology drug is particularly designed to target tumor tissues, minimizing systemic toxicity while maximizing anticancer activity. Capeta Nova interferes with DNA synthesis in rapidly dividing cancer cells leading to cell death, making it a preferred choice in treating colorectal, breast, and gastric cancers. Its oral administration facilitates outpatient treatment, eliminating the need for hospitalization. With a specific dosing regimen of 1250 mg/m² twice daily for 14 days followed by a 7-day rest period, Capeta Nova offers flexible treatment cycles managed by oncologists based on patient tolerance and toxicity levels. Packaged in boxes of 120 tablets, it ensures convenience and adherence in long-term chemotherapy protocols. This antimetabolite chemotherapy is indicated for adjuvant and metastatic treatment scenarios and is often used in combination with other chemotherapeutic agents to enhance efficacy. The product requires storage below 25°C in a dry, light-protected environment to maintain potency. Capeta Nova is contraindicated in pregnant and breastfeeding women due to potential teratogenic effects and requires careful monitoring for side effects such as hand-foot syndrome, diarrhea, nausea, and fatigue. It is a reliable oncology pharmaceutical from India catering primarily to healthcare institutions and specialized oncologists involved in cancer management.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Capecitabine 500 mg |
| Therapeutic Category | Oncology / Antimetabolite Chemotherapy |
| Mechanism of Action | Prodrug of 5-FU activated selectively in tumor cells, inhibits thymidylate synthase |
| Indications | Colorectal Cancer, Breast Cancer, Gastric Cancer |
| Administration Route | Oral tablet |
| Dosage Regimen | 1250 mg/m² twice daily for 14 days followed by 7 days rest |
| Packaging | Box of 120 tablets, 500 mg each |
| Storage Conditions | Store below 25°C, dry place, protect from light and moisture |
| Side Effects | Hand-foot syndrome, diarrhea, nausea, fatigue |
| Manufacturer | Nova |
| Attributes | Description |
|---|---|
| Generic Name | Capecitabine |
| Brand Name | Capeta Nova |
| Strength | 500 mg per tablet |
| Formulation | Tablet |
| Pack Size | 120 tablets per box |
| Country of Origin | India |
| Therapeutic Use | Treatment of solid tumors including colorectal, breast, and gastric cancer |
| Contraindications | Pregnancy, breastfeeding, severe renal impairment |
| Prescription Requirement | Prescription only, supervised by an oncologist |
| Regulatory Status | Oncology pharmaceutical |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Capeta Nova 500mg is a prodrug that is enzymatically converted to 5-FU selectively within tumor tissues, limiting exposure of healthy cells to 5-FU and thus reducing systemic toxicity compared to direct administration of 5-FU.
The typical dosing schedule is 1250 mg/m² taken orally twice daily for 14 days followed by a 7-day rest period, constituting a 21-day treatment cycle.
Yes, Capeta Nova 500mg is often used both as monotherapy and in combination regimens with other chemotherapeutic agents to improve treatment outcomes in metastatic and advanced cancers.
Capeta Nova 500mg tablets should be stored below 25°C in a dry place, protected from light and moisture to maintain their stability and potency.
Yes, patients with renal impairment require careful dose adjustments due to increased risk of toxicity when using Capeta Nova 500mg.
Country Of Origin: India
Product Name: Capeta Nova 500mg Tablet
Generic Name: Capecitabine 500 mg
Manufacturer: Nova (Capeta Nova brand)
Therapeutic Category:Oncology / Antimetabolite Chemotherapy
Product Description:
Capeta Nova 500mg contains Capecitabine, an oral fluoropyrimidine carbamate that acts as a prodrug of 5-Fluorouracil (5-FU).
It is specifically designed to be activated in tumor tissues, minimizing systemic toxicity and enhancing anticancer activity.
Capecitabine interferes with DNA synthesis in rapidly dividing cancer cells, leading to their death.
Indications:
• Colorectal Cancer (adjuvant and metastatic)
• Breast Cancer (metastatic, resistant to paclitaxel/anthracycline regimens)
• Gastric Cancer (advanced/metastatic)
• Used as monotherapy or in combination regimens with other chemotherapeutic agents
Mechanism of Action:
• Capecitabine is converted enzymatically into 5-FU within tumor cells.
• 5-FU inhibits thymidylate synthase, preventing DNA replication and cell division.
• Selective activation in tumor tissue reduces systemic toxicity compared to direct 5-FU therapy.
Dosage & Administration:
• Typical dose: 1250 mg/m² orally twice daily for 14 days, followed by 7 days rest (21-day cycle).
• Dose adjustments are based on toxicity and patient condition.
• Tablets should be swallowed with water within 30 minutes after a meal.
(Only to be prescribed and supervised by an oncologist.)
Key Benefits:
• Oral chemotherapy – no hospitalization required.
• Tumor-targeted activation for better safety profile.
• Effective in multiple solid tumors including breast, colon, and gastric cancers.
Packaging:
• Box of 120 tablets (500 mg each)
• Also available in 150 mg strength (varies by brand/market)
Storage:
• Store below 25°C, in a dry place.
• Protect from light and moisture.
Important Notes:
• For oncology use only.
• Side effects may include hand-foot syndrome, diarrhea, nausea, fatigue.
• Dose modification required in renal impairment.
• Contraindicated in pregnancy and breastfeeding.
Oncology products supplier from India
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
